{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(18)"],"submitter":["Kline C"],"pubmed_abstract":["<h4>Purpose</h4>PNOC003 is a multicenter precision medicine trial for children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG).<h4>Patients and methods</h4>Patients (3-25 years) were enrolled on the basis of imaging consistent with DIPG. Biopsy tissue was collected for whole-exome and mRNA sequencing. After radiotherapy (RT), patients were assigned up to four FDA-approved drugs based on molecular tumor board recommendations. H3K27M-mutant circulating tumor DNA (ctDNA) was longitudinally measured. Tumor tissue and matched primary cell lines were characterized using whole-genome sequencing and DNA methylation profiling. When applicable, results were verified in an independent cohort from the Children's Brain Tumor Network (CBTN).<h4>Results</h4>Of 38 patients en"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["3965-3978"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9475246"],"repository":["biostudies-literature"],"pubmed_title":["Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003."],"pmcid":["PMC9475246"],"pubmed_authors":["Kilburn L","Liang W","Zhang J","Prados M","Banerjee A","Yadavilli S","Nazarian J","Luks T","Kline C","Gupta N","Zhang B","Bonner ER","Villanueva-Meyer J","Resnick A","Molinaro A","Jain P","Packer RJ","Berens M","Kuhn J","Kraya A","Waszak SM","Crawford JR","Zhang Y","Gaonkar KS","Mueller S","Byron S","Kambhampati M","Rokita JL"],"additional_accession":[]},"is_claimable":false,"name":"Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003.","description":"<h4>Purpose</h4>PNOC003 is a multicenter precision medicine trial for children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG).<h4>Patients and methods</h4>Patients (3-25 years) were enrolled on the basis of imaging consistent with DIPG. Biopsy tissue was collected for whole-exome and mRNA sequencing. After radiotherapy (RT), patients were assigned up to four FDA-approved drugs based on molecular tumor board recommendations. H3K27M-mutant circulating tumor DNA (ctDNA) was longitudinally measured. Tumor tissue and matched primary cell lines were characterized using whole-genome sequencing and DNA methylation profiling. When applicable, results were verified in an independent cohort from the Children's Brain Tumor Network (CBTN).<h4>Results</h4>Of 38 patients en","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-05-27T22:31:16.392Z","creation":"2025-02-19T02:38:02.452Z"},"accession":"S-EPMC9475246","cross_references":{"pubmed":["35852795"],"doi":["10.1158/1078-0432.CCR-22-0803"]}}